Publications and presentations
AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial | The Oncologist | Oxford Academic
Authors: Kathryn E. Beckermann, Aviva G. Asnis-Alibozek, Michael B. Atkins, Bernard Escudier, Thomas E. Hutson, Vijay Kasturi, David F. McDermott, Sumanta K. Pal, Camillo Porta, Brian I. Rini, Elena Verzoni. Click here for link to article.
Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma (TIVO-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study
Authors: Brian I. Rini, Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott. Request for Reprint of The Lancet Oncology TIVO-3 Manuscript.
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
Authors: Pedro C. Barata, Alexander Chehrazi-Raffle, Kimberly D. Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K. Pal. Click here for link to article.
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
Authors: Julie E. Bauman, Nabil F. Saba, Denise Roe, Jessica R. Bauman, John Kaczmar, Aarti Bhatia, Jameel Muzaffar, Ricklie Julian, Steven Wang, Shethal Bearelly, Audrey Baker, Conor Steuer, Anshu Giri, Barbara Burtness, Sara Centuori, Carlos Caulin, Robert Klein, Kathylynn Saboda, Stefanie Obara, Christine H. Chung. Click here for link to article.